Skip to main content

LVH Diagnostic Criteria on ECG

Ecg criteria for lvh

Left Ventricular Hypertrophy (LVH) on ECG: Diagnostic Criteria Explained

Left ventricular hypertrophy refers to an increase in left ventricular muscle mass, most commonly due to chronic pressure overload such as long-standing hypertension or aortic stenosis. Although echocardiography is the gold standard for diagnosis, the ECG remains a widely used, inexpensive, and readily available screening tool. Several ECG criteria have been developed to identify LVH, each with its own strengths and limitations.


Why ECG Criteria Matter

ECG criteria for LVH are highly specific but relatively insensitive. This means that when criteria are met, LVH is likely present, but a normal ECG does not exclude LVH. ECG-detected LVH is clinically important because it independently predicts cardiovascular morbidity and mortality, including heart failure, arrhythmias, stroke, and sudden cardiac death.


Sokolow–Lyon Criteria

The Sokolow–Lyon criteria are among the oldest and most commonly taught ECG criteria for LVH. They rely on increased QRS voltage in precordial and limb leads, reflecting increased myocardial mass.


Diagnostic thresholds include:


R wave in aVL greater than 11 mm


R wave in V5 or V6 greater than 26 mm


Sum of S wave in V1 and R wave in V5 (or V6) greater than 35 mm



These criteria are easy to apply and widely used in clinical practice. However, they are less sensitive in obese patients, older adults, and those with chronic lung disease, and may overestimate LVH in young, thin individuals.


Cornell Voltage Criteria

The Cornell criteria improve diagnostic performance by incorporating both limb and precordial leads and by using sex-specific cutoffs.


The formula is:


R wave in aVL + S wave in V3



Diagnostic cutoffs:


Greater than 28 mm in men


Greater than 20 mm in women



Cornell criteria have better sensitivity than Sokolow–Lyon and correlate more closely with left ventricular mass on echocardiography. They are particularly useful in hypertensive patients and are commonly used in research studies and clinical trials.


Kaito and Spodick Criterion

The Kaito and Spodick criterion is a simpler qualitative rule based on R-wave progression in the lateral precordial leads.


Criterion:


R wave amplitude in V6 greater than R wave amplitude in V5



This finding reflects altered ventricular depolarization due to increased left ventricular mass. While not widely used alone, it can serve as a supportive finding when other voltage criteria are borderline or inconclusive.


Associated ECG Findings in LVH

Voltage criteria may be accompanied by additional ECG features that increase diagnostic confidence:


Left axis deviation


QRS widening


Left atrial enlargement (biphasic P wave in V1)


ST depression and T-wave inversion in lateral leads (LVH strain pattern)



The presence of a strain pattern is particularly significant, as it is associated with more advanced disease and worse prognosis.


Limitations of ECG Diagnosis

Despite multiple criteria, ECG has limited sensitivity for LVH. Factors that reduce ECG voltage include obesity, pericardial effusion, chronic obstructive pulmonary disease, and infiltrative cardiomyopathies. Conversely, high voltage may be seen in athletes and young individuals without true hypertrophy.


Clinical Implications

Detection of LVH on ECG should prompt further evaluation, usually with echocardiography, to confirm diagnosis and assess severity and etiology. Regression of ECG-LVH with antihypertensive therapy is associated with improved cardiovascular outcomes, making ECG a useful tool for long-term risk stratification and follow-up.


Conclusion

ECG criteria for left ventricular hypertrophy, including Sokolow–Lyon, Cornell, and Kaito–Spodick criteria, provide valuable diagnostic and prognostic information. While not definitive on their own, they remain an essential part of cardiovascular assessment and should always be interpreted in clinical context alongside imaging and patient risk factors.


Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.